Bronchiectasis in low- and middle-income countries: the importance of the wider view.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Azithromycin on serum FeNO, IgE, and eosinophil levels in bronchiectasis patients.Caspian journal of internal medicine · 2026
   Article
2. EMBARCing on a new era for bronchiectasis: a review series for the Seventh World Bronchiectasis Conference.European respiratory review : an official journal of the European Respiratory Society · 2024
   Article
3. Performance during the Glittre-ADL test between patients with and without post-tuberculosis bronchiectasis: A cross-sectional study.PloS one · 2023
   Article

Corrections and comments

• Comment on
  Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry.2023

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as